Project: Development of a new generation of optimized AAV Gene Therapy Vectors using Artificial Intelligence.
| Acronym | AAVanguard (Reference Number: 115712) |
| Duration | 15/09/2021 - 15/03/2024 |
| Project Topic | We will create a novel Artificial Intelligence platform enabling faster, more efficient gene therapy developments. This will empower R&D and academia scientists with a new generation of vectors with improved efficacy and safety. Their validation for central nervous system targeting will estimate the potential of the platform. The use of AAVanguard will reduce the development time, the number of animals and ultimately the costs associated to the development of the next generation of AAV capsids. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 15 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Aarhus University – Davide Mottin lab | Partner | Denmark |
| 2 | Genethon – Giuseppe Ronzitti lab | Partner | France |
| 3 | WhiteLab Genomics | Coordinator | France |